

Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

Complete this survey as described in the **Dialysis Event Protocol**.

Instructions: This survey is only for dialysis centers that provide in-center hemodialysis. If your center offers only home dialysis, please complete the Home Dialysis Center Practices Survey. Complete one survey per center. Surveys are completed for the current year. It is strongly recommended that the survey is completed in February of each year by someone who works in the center and is familiar with current practices within the center. Complete the survey based on the actual practices at the center, not necessarily the center policy, if there are differences. Please submit your responses to the questions in this survey electronically by logging into your NHSN facility.

*required to save as complete					
Facility	Facility ID #: *Survey Year:				
ESRD	ESRD Network #:				
A. Dial	lysis Center Information				
A.1. G	eneral				
*1.	What is the ownership of your dialysis center? (choose one	e)			
	☐ Government ☐ Not for profit	☐ For profit			
*2.	a. What is the location/hospital affiliation of your dialysis ce	enter? (choose one)			
	☐ Freestanding ☐ Hospital based	$\square$ Freestanding but owned by a	hospital		
	b. If hospital-based or hospital-owned, is your center affilia	ated with a teaching hospital?	□ Yes □ No		
*3.	Is your facility accredited by an organization other than CM a. If yes, specify (choose one)	MS?	□ Yes □ No		
	☐ Joint Commission ☐ National Dialysis Accreditation Commission (NDAC)	☐ Accreditation Commission for Health Care (ACHC)	☐ Other (specify)		
*4.	a. What types of dialysis services does your center offer?	(select all that apply)			
	☐ In-center daytime ☐ In-center nocturnal hemodialysis hemodialysis	☐ Peritoneal dialysis ☐ Ho	ome hemodialysis		
	b. What patient population does your center serve? (select	t one)			
	☐ Adult only ☐ Pediatric only	☐ Mixed: adult and pediatric			
*5.	How many in-center hemodialysis stations does your center	er have?			
*6.	Is your center part of a group or chain of dialysis centers?		☐ Yes ☐ No		
	a. If yes, what is the name of the group or chain?				
*7.	Do you (the person primarily responsible for collecting data care in the dialysis center?	a for this survey) perform patient	☐ Yes ☐ No		
*8.	Is there someone at your dialysis center in charge of infect	tion control?	☐ Yes ☐ No		
	a. If yes, which best describes this person? (if >1 per	rson in charge, select all that app	ly)		
	$\square$ Hospital-affiliated or other infection control $\mu$	practitioner comes to our unit			
	☐ Dialysis nurse or nurse manager				
	☐ Dialysis center administrator or director				
	$\square$ Dialysis education specialist				
	☐ Patient care technician				
	☐ Other, specify:				
Δssuranc	ce of Confidentiality: The voluntarily provided information obtained in this surveillan	oce system that would permit identification of an	v individual or institution is		
collected v	with a guarantee that it will be held in strict confidence, will be used only for the purpo ividual, or the institution in accordance with Sections 304, 306 and 308(d) of the Publi	oses stated, and will not otherwise be disclosed	or released without the consent		
sources, g required to aspect of	porting burden of this collection of information is estimated to average 1.75 hours per in gathering and maintaining the data needed, and completing and reviewing the collection to respond to a collection of information unless it displays a currently valid OMB control this collection of information, including suggestions for reducing this burden to CDC, I RA (0920-0666).	ion of information. An agency may not conduct ol number. Send comments regarding this burd	or sponsor, and a person is not len estimate or any other		



Form	App	rove
OMB No. 0	920	-066
E	Ехр.	Date
www.cdc	.aov	/nhs

*9.	lational Healthcare afety Network Does your center provide di assisted dialysis in nursing					www.c	cdc.gov/nhsn
a. *10.	hospitals)?  If yes, in how many long-ter Is there a dedicated vascula center?			r (either full or p	art-time) at your	□ Yes	□ No
A.2. Iso	plation and Screening						
*11.	Does your center have capa	acity to isolate p	atients with	n hepatitis B?			
	☐ Yes, use hepatitis B isola			•	tion area □ No he	patitis B iso	lation
*12.	Are patients routinely isolate yes, select all that apply)			•		•	
	□ No, none	☐ Hepatitis	С	☐ Active	e tuberculosis (TB dise	ease)	
	☐ Vancomycin-resistan	t <i>Enterococcus</i>	(VRE)				
	☐ Methicillin-resistant S	Staphylococcus a	aureus (MF	RSA) $\square$ Other	, specify:	<del> </del>	
*13.	Are patients routinely assess precautions, such as infected a. If yes, when does the Before the patient □ Once the patient □ Other (specify)	ed wounds with one of the country assessment on the country and the country are considered with the country and the country are considered with the country are considered wounds with the country are considered with the considered	drainage, f most often Itment area	ecal incontinenc occur? (select c a (e.g., at check-	e or diarrhea?	□ Yes om)	s □ No
*14.	Does your center routinely sto your center?  a. If yes, what method  Tuberculin Skin	is used to scree	en? (select	all that apply)		on □ Yes —	s □ No
A.3. Pa	atient Records and Surveillan	ce					
*15.	Does your center maintain r hemodialysis treatment for o	ecords of the <b>st</b>		re each patient r	eceived their	□ Ye:	s 🗆 No
*16.	Does your center maintain r treatment for every treatmen		<b>achine</b> us	ed for each patie	ent's hemodialysis	□ Yes	s □ No
*17.	If a patient from your center infection contributed to their □ Always □ Often	hospital admiss	sion?	en is your center □ Rarely		bloodstrear	
*18.	How often is your center ab	le to obtain a pa	tient's mic				
	☐ Always ☐ Often	□ Some	times	☐ Rarely	□ Never □	l N/A – not p	oursued
*19.	Which of the following infect (select all that apply)						
	☐ Peritonitis	☐ Exit site infe	ction	☐ Tunnel infection	on   🗆 Other (specif	y)	
*20.	Which of the following even (select all that apply)	ts in your home	hemodialy	sis patients does	s your center routinely	track?	
	☐ Bloodstream infection☐ Vascular access site infection		า	ement bloodline separa	☐ Other (specif	y)	
	respond to the following of s to current or most recent Fo				ur center for the <u>first</u>	week of Fe	ebruar <u>y</u>
B. Pati	ent and staff census						
*21. *22.	Was your center operational How many MAINTENANCE week of February?  Of these, indicate the numb a. In-center hemodialy b. Home hemodialysis c. Peritoneal dialysis:	i, NON-TRANSI er who received sis:	ENT dialys	-	ere assigned to your c	☐ Ye: enter during	





How many acute kidney injury (AKI) patients received hemodialysis in your center during the first week of February?		National Health	ocare York				www.cd	c.gov/nhsn
of February? Include only staff who had direct contact with dialysis patients or equipment:  Of these, how many were in each of the following categories?  a. Nurse/nurse assistant:  b. Dialysis patient-care technician:  c. Dialysis patient-care technician:  d. Social worker:  d. Other:  C. Vaccines  25. Of the in-center hemodialysis patients counted in question 22a, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least oses of hepatitis B vaccine (ever)?  727. Of the pertioneal dialysis patients counted in question 22c, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most.recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most.recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most.recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most.recent flu season?  *29. Dose your center use standing orders to allow nurses to administer any of the vaccines   Yes   No mentioned above to patients without a specific physician order?  *20. Which type of pneumococcal vaccine does your center offer to patients? (choose one)    Polysaccharide (i.e., PSV23) only   Goniquate (e.g., PCV13) only   Both polysaccharide & conjugate   Neither offered	*23.			its received hemodia	alysis	s in your center during the f	irst week of	:
a. Nurse/nurse assistant:	*24.							rst week
b. Dialysis biomedical technician: c. Dialysis biomedical technician: d. Social worker: d. Other:  C. Vaccines  *25. Of the in-center hemodialysis patients counted in question 22a, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)?  *26. Of the home hemodialysis patients counted in question 22b, how many received: a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season? c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)?  *27. Of the pertioneal dialysis patients counted in question 22b, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season? c. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines		Of thes	e, how many were in each of the fo	llowing categories?				
c. Dialysis biomedical technician:		a.	Nurse/nurse assistant:		a.	Dietitian:		
d. Social worker: d. Other:  C. Vaccines  *25. Of the in-center hemodialysis patients counted in question 22a, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *28. Of the patient care staff members counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines		b.	Dialysis patient-care technician:		b.	Physicians/physician assis	stant:	
*25. Of the in-center hemodialysis patients counted in question 22a, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *26. Of the home hemodialysis patients counted in question 22b, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *27. Of the peritoneal dialysis patients counted in question 22c, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  *28. Of the patient care staff members counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines   Yes   No mentioned above to patients without a specific physician order?  *20. Which type of pneumococcal vaccine does your center offer to patients? (choose one)    Polysaccharide (i.e., PPSV23) only   Conjugate (e.g., PCV13) only   Both polysaccharide & conjugate   Neither offered  D. Hepatitis B and C  D.1. Hepatitis B and C  D.2. Hepatitis B and C  D.3. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center;  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination?)? Do not include patients who were antigen positive before they were first		C.	Dialysis biomedical technician:		C.	Nurse practitioner:		
*25. Of the in-center hemodialysis patients counted in question 22a, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *26. Of the home hemodialysis patients counted in question 22b, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *27. Of the peritoneal dialysis patients counted in question 22c, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  *28. Of the patient care <u>staff members</u> counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines		d.	Social worker:		d.	Other:		
a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  *27. Of the <u>peritoneal dialysis patients</u> counted in question 22c, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  *28. Of the patient care <u>staff members</u> counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines   Yes   No mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to <u>patients</u> ? (choose one)    Polysaccharide & conjugate (e.g., PCV13) only   Both polysaccharide & conjugate   Neither offered  D. Hepatitis B and C  D.1. Hepatitis B and C  D.1. Hepatitis B and C  D.2. The patients of the patients by the vere hepatitis B surface ANTIGEN (HBSAq) positive in the first week of February, how many were positive when first admitted to your center?  i. Of these patients who were hepatitis B surface ANTIGEN (HBSAq) positive in the first week of February, how many patients And newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥ 1 hemodialysis patient who reverse seroconverted   Yes   No (i.e., had evidence of resolved hepatitis B infection followed	C. Va	ccines						
a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *26. Of the home hemodialysis patients counted in question 22b, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *27. Of the <u>peritoneal dialysis patients</u> counted in question 22c, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *28. Of the patient care <u>staff members</u> counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines	*25.	Of the	in-center hemodialysis patients cou	inted in question 22a	a. ho	w many received:		
b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least a doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *28. Of the patient care <u>staff members</u> counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)  Polysaccharide (i.e., PPSV23) only  Conjugate (e.g., PCV13) only  Both polysaccharide & conjugate  Neither offered  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBSAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBSAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBSAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of			· ·	•	.,			
*26. Of the home hemodialysis patients counted in question 22b, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)?  Of the peritoneal dialysis patients counted in question 22c, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season?  *28. Of the patient care staff members counted in question 24, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)    Polysaccharide (i.e., PPSV23) only   Conjugate (e.g., PCV13) only   Both polysaccharide & conjugate   Neither offered  D.Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive to positive during the prior 12 months (i.e., in the past year, how many patients and newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted   Yes   No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			•	• • • • • • • • • • • • • • • • • • • •	— flu s	eason?		
*26. Of the home hemodialysis patients counted in question 22b, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season? c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season? c. At least one dose of pneumococcal vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season? c. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines  b. The influenza (flu) vaccine does your center offer to patients? (choose one)  Polysaccharide (i.e., PPSV23) only  Conjugate (e.g., PCV13) only  Both polysaccharide & conjugate  Neither offered  D. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  1*32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted    Yes   No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			• •					
a. At least 3 dose's of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the <u>current/most recent flu</u> season? c. At least one dose of pneumococcal vaccine (ever)?  *27. Of the <u>peritoneal dialysis patients</u> counted in question 22c, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the <u>current/most recent flu</u> season? c. At least one dose of pneumococcal vaccine (ever)?  *28. Of the patient care <u>staff members</u> counted in question 24, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the <u>current/most recent flu</u> season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B and C  D.1. Hepatitis B and C  D.2. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B	*26		·	. ,				
b. The influenza (flu) vaccine for the <u>current/most recent flu season?</u> c. At least one dose of pneumococcal vaccine (ever)?  *27. Of the <u>peritoneal dialysis patients</u> counted in question 22c, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the <u>current/most recent flu season?</u> c. At least one dose of pneumococcal vaccine (ever)?  *28. Of the patient care <u>staff members</u> counted in question 24, how many received: a. At least 3 doses of hepatitis B vaccine (ever)? b. The influenza (flu) vaccine for the <u>current/most recent flu season?</u> *29. Dose your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to <u>patients</u> ? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted  □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitits B	20.				JVV 11	iany received.		
*27. Of the peritoneal dialysis patients counted in question 22c, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of pneumococcal vaccine (ever)?  *28. Of the patient care staff members counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February.  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) positive to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  1*32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B		b.	The influenza (flu) vaccine for the	current/most recent t				
a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least 3 doses of pneumococcal vaccine (ever)?  *28. Of the patient care staff members counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine dose your center offer to patients? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in_center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center)  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted  [ \text{ \tex		C.	At least one dose of pneumococca	al vaccine (ever)?				
b. The influenza (flu) vaccine for the current/most recent flu season?  c. At least one dose of pneumococcal vaccine (ever)?  *28. Of the patient care staff members counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  1	*27.				v ma	any received:		
c. At least one dose of pneumococcal vaccine (ever)?								
*28. Of the patient care staff members counted in question 24, how many received:  a. At least 3 doses of hepatitis B vaccine (ever)?  b. The influenza (flu) vaccine for the current/most recent flu season?  *29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)    Polysaccharide (i.e., PPSV23) only   Conjugate (e.g., PCV13) only   Both polysaccharide & conjugate   Neither offered  D. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:    *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted   Yes   No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B					tiu s	eason?		
a. At least 3 doses of hepatitis B vaccine (ever)?	*20		·	. ,		— my received.		
b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?	^Z8.		•	•		ny received:		
*29. Does your center use standing orders to allow nurses to administer any of the vaccines mentioned above to patients without a specific physician order?  *30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			•	• • • • • • • • • • • • • • • • • • • •		0		
*30. Which type of pneumococcal vaccine does your center offer to patients? (choose one)  □ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted  □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			• •			•		
□ Polysaccharide (i.e., PPSV23) only □ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February? □ i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center? □ b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center: □ 1832. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted	*29.					r any of the vaccines	☐ Yes	□ No
□ Conjugate (e.g., PCV13) only □ Both polysaccharide & conjugate □ Neither offered  D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a: a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February? □ i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center? □ b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center: □ *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B	*30.	Which t	type of pneumococcal vaccine does	s your center offer to	pat	ients? (choose one)		
D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B		□ F	Polysaccharide (i.e., PPSV23) only					
D. Hepatitis B and C  D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted  □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			Conjugate (e.g., PCV13) only					
D.1. Hepatitis B  *31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted □ Yes □ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			Both polysaccharide & conjugate					
*31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted ☐ Yes ☐ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			Neither offered					
*31. Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis PATIENTS from question 22a:  a. How many were hepatitis B surface <b>ANTIGEN</b> (HBsAg) positive in the first week of February?  i. Of these patients who were hepatitis B surface <b>ANTIGEN</b> (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?  b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted ☐ Yes ☐ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B	D. He	patitis B	and C					
<ul> <li>a. How many were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February?</li></ul>	D.1. F	lepatitis B						
<ul> <li>i. Of these patients who were hepatitis B surface ANTIGEN (HBsAg) positive in the first week of February, how many were positive when first admitted to your center?</li> <li>b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:</li> <li>*32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted ☐ Yes ☐ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B</li> </ul>	*31.				-	·		
b. How many patients converted from hepatitis B surface ANTIGEN (HBsAg) negative to positive during the prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted ☐ Yes ☐ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B		a.	•	, ,				
prior 12 months (i.e., in the past year, how many patients had newly acquired hepatitis B virus infection; not as a result of vaccination)? Do not include patients who were antigen positive before they were first dialyzed in your center:  *32. In the past year, has your center had ≥1 hemodialysis patient who reverse seroconverted ☐ Yes ☐ No (i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B			February, how many were	positive when first a	admi	tted to your center?		
(i.e., had evidence of resolved hepatitis B infection followed by reappearance of hepatitis B		b.	prior 12 months (i.e., in the past ye not as a result of vaccination)? Do	ear, how many patier	nts h	nad newly acquired hepatitis	s B virus inf	ection;
	*32.	(i.e., h	ad evidence of resolved hepatitis B				□ Yes	□ No

D.2. I	Hepatitis C		
*33.	Does your center routinely screen hemodialysis patients for <b>hepatitis C</b> antibody (anti-HCV)	☐ Yes	



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

*34.	Does y any o	Imission to your center? ( <i>Note: This is NOT hepatitis B core antibody</i> ) your center routinely screen hemodialysis patients for hepatitis C antibody (anti-HCV) at	′es □ No
	ii yes	, now frequently?  ☐ Twice annually ☐ Annually ☐ Other, specify:	
*35.	Of the	MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients counted in	
		on 22a,	
	ä.	How many were hepatitis C antibody positive in the first week of February?  i. Of these patients who were hepatitis C antibody positive in the first week of February, how positive when first admitted to your center?	many were
	b.	How many patients converted from hepatitis C antibody negative to positive during the prior 12 (i.e., in the past year, how many patients had newly acquired hepatitis C infection)? Do not ine patients who were anti-HCV positive before they were first dialyzed in your center:	
E. D	ialysis F	Policies and Practices	
E.1.	Dialyzer	· Reuse	
*36.	-	your center reuse dialyzers for any patients?	es □ No
	If yes,		
	a.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients counted in 22a, he them participate in dialyzer reuse?	ow many of
	b.	Does your center routinely test reverse osmosis (R.O.) water from the reuse room for $\Box$ Y culture and endotoxin whenever a reuse patient has a pyrogenic reaction?	'es □ No
	C.	Of all reused dialyzers at your center, how many undergo refrigeration prior to reprocessing?	
		□ All □ Most □ Some □ Few □ None	
	d.	Is there a limit to the number of times a dialyzer is used?	
		☐ Yes (indicate number):	
	•	□ No limit as long as dialyzer meets certain criteria (e.g., passes pressure leak test, etc.)	vr 00000
	e.	Of all reused dialyzers in your center, how many of them have sealed (non-removable) heade  □ All □ Most □ Some □ Few □ None	r caps?
	f.	Where are dialyzers reprocessed?	
	•	☐ Dialyzers are reprocessed at our center only	
		☐ Dialyzers are transported to an off-site facility for reprocessing only	
		☐ Both at our center and off-site	
		If any dialyzers are reprocessed at the facility,	
		i. How is dialyzer header cleaning performed? (select all that apply)	
		☐ Automated machine (e.g., RenaClear® System)	
		☐ Spray device (e.g., ASSIST® header cleaner)	
		$\square$ Insertion of twist-tie or other instrument to break up clots	
		☐ Disassemble dialyzer to manually clean	
		☐ Other, specify:	
		☐ No separate header cleaning step performed	
		ii. How are dialyzers reprocessed?	
		☐ Automated reprocessing equipment	
		☐ Manual reprocessing	

#### E.2. Water/Dialysate

\*37. What type of dialysate is used for in-center hemodialysis patients at your center? (choose one)



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

b. Dialysate from the patient's dialysis machine  E.3 Priming Practices  *39. Does your center use hemodialysis machine Waste Handling Option (WHO) ports?  *40. Are any patient in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial  Multi-dose vial  Pre-packaged syringe  N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient?  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (check the individual dialysis stations  On a mobile medication cart within the treatment area  At a fixed location within the patient treatment area (e.g., at nurses' station)  At a fixed location removed from the patient treatment area (not a room)  In a separate medication room  In a pharmacy  Other, specify:	☐ Yes☐ Yes☐ Yes☐ Yes☐ Yes☐ Hes☐ Yes☐ Yes☐ Yes☐ Yes☐ Yes☐ Yes☐ Yes☐ Y	□ No
*38. Does your center routinely test the following whenever a patient has a pyrogenic reaction?  a. Patient blood culture b. Dialysate from the patient's dialysis machine  E.3 Priming Practices  *39. Does your center use hemodialysis machine Waste Handling Option (WHO) ports?  *40. Are any patient in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial Multi-dose vial Pre-packaged syringe N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient?  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (chelling in the individual dialysis stations)  On a mobile medication cart within the treatment area  At a fixed location within the patient treatment area (e.g., at nurses' station)  At a fixed location removed from the patient treatment area (not a room)  In a separate medication room  In a pharmacy  Other, specify:	☐ Yes ☐ Yes ☐ Yes ☐ Yes ☐ Yes	□ No □ No
a. Patient blood culture b. Dialysate from the patient's dialysis machine  E.3 Priming Practices  *39. Does your center use hemodialysis machine Waste Handling Option (WHO) ports?  *40. Are any patient in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial	☐ Yes ☐ Yes ☐ Yes ☐ Yes ☐ Yes	□ No □ No
*39. Does your center use hemodialysis machine Waste Handling Option (WHO) ports?  *40. Are any patient in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial Multi-dose vial Pre-packaged syringe N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient?  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (chat the individual dialysis stations  On a mobile medication cart within the treatment area  At a fixed location within the patient treatment area (e.g., at nurses' station)  At a fixed location removed from the patient treatment area (not a room)  In a separate medication room  In a pharmacy  Other, specify:   Odder Samuel Carlo (WHO) ports  Description (WHO) p	☐ Yes ☐ Yes	□ No
*39. Does your center use hemodialysis machine Waste Handling Option (WHO) ports?  *40. Are any patient in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial Multi-dose vial Pre-packaged syringe N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient?  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (chart in dividual dialysis stations  On a mobile medication cart within the treatment area  At a fixed location within the patient treatment area (e.g., at nurses' station)  At a fixed location removed from the patient treatment area (not a room)  In a separate medication room  In a pharmacy  Other, specify:  Other, specify:	□ Yes	□ No
*40. Are any patient in your center "bled onto the machine" (i.e., where blood is allowed to reach or almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial Multi-dose vial Pre-packaged syringe N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient?  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (chat the individual dialysis stations  On a mobile medication cart within the treatment area  At a fixed location within the patient treatment area (e.g., at nurses' station)  At a fixed location removed from the patient treatment area (not a room)  In a separate medication room  In a pharmacy  Other, specify:  Other, specify:	□ Yes	□ No
almost reach the prime waste receptacle or WHO port)?  E.4. Injection Practices  *41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial	□ Yes	□ No
*41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial Multi-dose vial Pre-packaged syringe N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient?  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (chat the individual dialysis stations On a mobile medication cart within the treatment area At a fixed location within the patient treatment area (e.g., at nurses' station) At a fixed location removed from the patient treatment area (not a room) In a separate medication room In a pharmacy Other, specify:  Other, specify:		
*41. What form of erythropoiesis stimulating agent (ESA) is most often used in your center?  Single-dose vial		
Single-dose vial ☐ Multi-dose vial ☐ Pre-packaged syringe ☐ N/A  a. Is ESA from one single-dose vial or syringe administered to more than one patient? ☐  *42. What are medications most commonly drawn into syringes to prepare for patient administration? (ch ☐ At the individual dialysis stations ☐ On a mobile medication cart within the treatment area ☐ At a fixed location within the patient treatment area (e.g., at nurses' station) ☐ At a fixed location removed from the patient treatment area (not a room) ☐ In a separate medication room ☐ In a pharmacy ☐ Other, specify:		
*42. What are medications most commonly drawn into syringes to prepare for patient administration? (ch At the individual dialysis stations  On a mobile medication cart within the treatment area  At a fixed location within the patient treatment area (e.g., at nurses' station)  At a fixed location removed from the patient treatment area (not a room)  In a separate medication room  In a pharmacy  Other, specify:		
☐ At the individual dialysis stations ☐ On a mobile medication cart within the treatment area ☐ At a fixed location within the patient treatment area (e.g., at nurses' station) ☐ At a fixed location removed from the patient treatment area (not a room) ☐ In a separate medication room ☐ In a pharmacy ☐ Other, specify:	choose (	one)
<ul> <li>□ At a fixed location within the patient treatment area (e.g., at nurses' station)</li> <li>□ At a fixed location removed from the patient treatment area (not a room)</li> <li>□ In a separate medication room</li> <li>□ In a pharmacy</li> <li>□ Other, specify:</li> </ul>		
☐ At a fixed location removed from the patient treatment area (not a room) ☐ In a separate medication room ☐ In a pharmacy ☐ Other, specify:		
☐ In a separate medication room ☐ In a pharmacy ☐ Other, specify:		
☐ In a pharmacy ☐ Other, specify:		
Other, specify:		
*43 Do technicians administer any IV medications or infusates (e.g., henarin, saline) in your center?		
	☐ Yes	
*44. What form of <b>saline flush</b> is most commonly used?		
☐ Manufacturer pre-filled saline syringes☐ Flushes are drawn from single-use saline vials		
☐ Flushes are drawn from multi-dose saline vials		
☐ Flushes are drawn from the patient's designated saline bag used for dialysis		
Flushes are drawn from the patient's dialysis circuit		
Flushes are drawn from a common saline bag used for all patients		
Other (specify):		
E.5. Antibiotic Use		
*45. Does your center use the following means to restrict or ensure appropriate antibiotic use?		
_	☐ Yes	
D. FUHIDIAIVIESIUCIOUS	⊔ 162	
	□ Yes	I I Nc
c. Antibiotic use approval process	□ Yes □ Yes	
c. Antibiotic use approval process d. Automatic stop orders for antibiotics	☐ Yes	
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)?	☐ Yes	
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)?  □ Always □ Often □ Sometimes □ Rarely □ Never	☐ Yes	
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before to cultures are drawn (or without performing blood cultures)?  □ Always □ Often □ Sometimes □ Rarely □ Never  E.6. Prevention Activities	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before to cultures are drawn (or without performing blood cultures)?  □ Always □ Often □ Sometimes □ Rarely □ Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)? □ Always □ Often □ Sometimes □ Rarely □ Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)? □ Always □ Often □ Sometimes □ Rarely □ Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply) □ Catheter reduction	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)?  Always  Often  Sometimes  Rarely  Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)  Catheter reduction  Hand hygiene	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before k cultures are drawn (or without performing blood cultures)?  Always  Often  Sometimes  Rarely  Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)  Catheter reduction  Hand hygiene  Bloodstream infection prevention	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)?  Always  Often  Sometimes  Rarely  Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)  Catheter reduction  Hand hygiene	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before to cultures are drawn (or without performing blood cultures)?  Always  Often  Sometimes  Rarely  Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)  Catheter reduction  Hand hygiene  Bloodstream infection prevention  Patient education/engagement for infection prevention	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before to cultures are drawn (or without performing blood cultures)?  Always  Often  Sometimes  Rarely  Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)  Catheter reduction  Hand hygiene  Bloodstream infection prevention  Patient education/engagement for infection prevention  Increase vaccination rates  Decrease/improve use of antibiotics  Improve general infection control practices	☐ Yes	□ No
c. Antibiotic use approval process d. Automatic stop orders for antibiotics  *46. In your center, how often are antibiotics administered for a suspected bloodstream infection before be cultures are drawn (or without performing blood cultures)?  Always Often Sometimes Rarely Never  E.6. Prevention Activities  *47. Has your center participated in any national or regional infection prevention-related initiatives in the past year?  a. If yes, what is the primary focus of the initiative(s)? (if >1 initiative, select all that apply)  Catheter reduction Hand hygiene Bloodstream infection prevention Patient education/engagement for infection prevention Increase vaccination rates Decrease/improve use of antibiotics	☐ Yes	□ No

E.6. Prevention Activities (continued)



	arety Wetw	<ul> <li>b. If yes, is your center actively participating in any of the following prevention initiatives (seapply):</li> </ul>	elect all that
ı		CDC Making Dialysis Safer for Patients Coalition – facility-level participation	
		<ul> <li>CDC Making Dialysis Safer for Patients Coalition – corporate- or other organization participation</li> </ul>	-level
	_	☐ The Standardizing Care to improve Outcomes in Pediatric End Stage Renal Diseas Collaborative Peritoneal Dialysis Catheter-related Infection Project	e (SCOPE)
ı		SCOPE Collaborative Hemodialysis Access-related Infection Project	
ı		None of the above	
	*48.	In the past year, has your center's medical director participated in a leadership or educational activity as part of the American Society of Nephrology's (ASN) Nephrologists Transforming Dialysis Safety (NTDS) Initiative?	□ Yes □ N
	*49.	Does your center follow <u>CDC-recommended Core Interventions</u> to prevent bloodstream infections hemodialysis patients?	s in
ı		☐ Yes, all ☐ Yes, some ☐ No, none	
ı	*50.	Does your center perform hand hygiene audits of staff monthly (or more frequently)?	☐ Yes ☐ No
	*51.	Does your center perform observations of staff vascular access care and catheter accessing practices quarterly (or more frequently)?	□ Yes □ No
	*52.	Does your center perform staff competency assessments for vascular access care and catheter accessing annually (or more frequently)?	□ Yes □ No
I	E.7. P€	eritoneal Dialysis	
		during dressing change?  a. If yes, what type of ointment is most commonly used? (select one)  Gentamicin  Mupirocin  Povidone-iodine  Bacitracin/polymyxin B (e.g., Polysporin®)  Bacitracin/neomycin/polymyxin B (triple antibiotic)  Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)  Other, specify:	
I	F. Vas	cular Access	
I		eneral Vascular Access Information	
	*54.	Of the MAINTENANCE, NON-TRANSIENT in-center hemodialysis patients from question 22a, he received hemodialysis through each of the following access types during the first week of Februara. AV fistula:  b. AV graft:  c. Tunneled central line:  d. Nontunneled central line:  e. Other vascular access device (e.g., HeRO®):	
	*55.	Of the MAINTENANCE, NON-TRANSIENT home hemodialysis patients from question 22b, how hemodialysis through each of the following access types during the first week of February?  a. AV fistula:  b. AV graft:  c. Tunneled central line:  d. Nontunneled central line:  e. Other vascular access device (e.g., HeRO®):	many received



Form Approved OMB No. 0920-0666 Exp. Date: www.cdc.gov/nhsn

F.2.	Arteriovenous (AV) Fistulas or Grafts
*56.	Before prepping the fistula or graft site for rope-ladder cannulation, what is the site most often <u>cleansed</u> with?  Soap and water  Alcohol-based hand rub  Antiseptic wipes  Other, specify:
*57.	(select one)  □ Alcohol □ Chlorhexidine without alcohol □ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®) □ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol □ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol □ Other, specify: □ Nothing  a. What form of this skin antiseptic is used to prep fistula/graft sites? □ Multiuse bottle (e.g., poured onto gauze) □ Pre-packaged swabstick/spongestick □ Pre-packaged pad □ Other, specify: □ N/A
*58.	Of the AV fistula patients from question 54a, how many had buttonhole cannulation?  If any <u>in-center</u> hemodialysis patients undergo buttonhole cannulation,  a. When buttonhole cannulation is performed for in-center hemodialysis patients:  i. Who most often performs it?  □ Nurse □ Patient (self-cannulation) □ Technician □ Other, specify:  ii. Before cannulation, what is the buttonhole site most often prepped with? (select the one most commonly used) □ Alcohol □ Chlorhexidine without alcohol □ Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®) □ Povidone-iodine (or tincture of iodine) □ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol □ Other, specify: □ Nothing  iii. Is antimicrobial ointment (e.g., mupirocin) routinely used at buttonhole □ Yes □ N cannulation sites to <b>prevent</b> infection?
*59.	·

F.2. Arteriovenous (AV) Fistulas or Grafts (continued)



		<ul> <li>ii. Before cannulation, what is the buttonhole site most often prepped with? (select the one most commonly used)</li></ul>
	F.3. Hemodia	ysis Catheters
		accessing the hemodialysis catheter, what are the <b>catheter hubs</b> most commonly prepped with?
2	(select	Alcohol
a. o.		Chlorhexidine without alcohol
	_	Chlorhexidine with alcohol (e.g., Chloarprep™, PDI Prevantics®)
c. d.		Povidone-iodine (or tincture of iodine)
a. e.		Sodium hypochlorite solution (e.g., Alcavis) without alcohol
٠.		Sodium hypochlorite solution (e.g., Alcavis) followed by alcohol
g.		Other, specify:
า.		Nothing
	a.	What form of this antiseptic/disinfectant is used to prep the catheter hubs?
		☐ Multiuse bottle (e.g., poured onto gauze)
ζ.		☐ Pre-packaged swabstick/spongestick
		☐ Pre-packaged pad
n.		□ Other, specify:
٦.		□ N/A
Э.		modialysis catheter hubs routinely scrubbed after the cap is removed and before $\ \square$ Yes $\ \square$ No sing the catheter (or before accessing the catheter via a needleless connector device, if used)?
q.	skin) m	the hemodialysis catheter dressing is changed, what is the exit site (i.e., place where the catheter enters th nost commonly prepped with? (select one) Alcohol
S.		Chlorhexidine without alcohol (e.g., Chloarprep™, PDI Prevantics®)
J.		Povidone-iodine (or tincture of iodine)
/. N.		Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol
ν. Κ.		Other, specify:
		Nothing
	a.	What form of this antiseptic/disinfectant is used at the exit site? ☐ Multiuse bottle (e.g., poured onto gauze)
		☐ Pre-packaged swabstick/spongestick
		☐ Pre-packaged pad
		Other, specify:
		□ N/A



	F.3. H	Hemodialysis Catheters (continued)	
у.	*63.	For <b>hemodialysis catheters</b> , is antimicrobial ointment routinely applied to the exit site during dressing	•
Z.		☐ Yes ☐ No ☐ N/A – chlorhexidine-impregnated dressing is routinely used. If yes, what type of ointment is most commonly used? (select one) ☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple) ☐ Gentamicin ☐ Bacitracin/polymyxin B (e.g., Polysporin®) ☐ Mupirocin ☐ Bacitracin/neomycin/polymyxin B (triple antibiotic) ☐ Povidone-iodine ☐ Other, specify:	sea
aa.	*64.	Who <u>most often</u> accesses hemodialysis catheters for treatment in your center? (select one)  ☐ Nurse ☐ Technician ☐ Other, specify:	
bb.	*65.	Who <u>most often</u> performs hemodialysis exit site care in your center? (select one) ☐ Nurse ☐ Technician ☐ Other, specify:	
CC.	*66.	Are antimicrobial lock solutions used to <b>prevent</b> hemodialysis catheter infections in your center? $\Box$ Yes, for all catheter patients $\Box$ Yes, for some catheter patients $\Box$ No	
dd.		a. If yes, which lock solution is most commonly used? (select one)	
ee.		☐ Sodium citrate ☐ Taurolidine ☐ Gentamycin ☐ Ethanol	
ff.	*67.	☐ Vancomycin ☐ Multi-component lock solution or other, specify:Are needleless closed connector devices (e.g., Tego®, Q-Syte™) used on hemodialysis ☐ Y	′es □ No
"	07.	catheters in your center?	C3 1110
		a. If yes, for which patients:	
		☐ In-center hemodialysis patients only	
		<ul><li>☐ Home hemodialysis patients only</li><li>☐ Both</li></ul>	
gg.	*68.	Are any of the following routinely used for hemodialysis catheters in your center? (select all	
99		that apply)	
		Chlorhexidine dressing (e.g., Biopatch®, Tegaderm™ CHG)	
		Other antimicrobial dressing (e.g., silver-impregnated)  Antiseptic-impregnated catheter cap/port protector:	'es □ No
		3M™ Curos™ Disinfecting Port Protectors	′es □ No
		ClearGuard® HD end caps □ Y	
		Antimicrobial-impregnated hemodialysis catheters $\ \square\ Y$	'es □ No
hh.	*69.	Does your center provide hemodialysis catheter patients with supplies to allow for changing catheter of outside the dialysis center?	-
ii.	*70.	☐ Yes, routinely for all or most patients with a catheter ☐ Yes, only for select patients with a catheter	
	70.	<ul> <li>a. Does your center educate patients with hemodialysis catheters on how to shower with the catheter?</li> <li>best response)</li> </ul>	
jj.		☐ Yes, routinely for all or most patients with a ☐ No, patients with hemodialysis cathe catheter ☐ instructed against showering	ters are
		catheter instructed against showering $\square$ Yes, only for select patients with a catheter $\square$ No, education and instructions are no	ot provided
		on this topic	or provided
kk.		b. Does your center provide hemodialysis catheter patients with a protective catheter cover (e.g., Show	wer Shield®
		Cath Dry™) to allow them to shower?  ☐ Yes, routinely for all or most patients with a catheter	
		☐ Yes, only for select patients with a catheter	
		□ No	
	Comn	nments:	



Safety Network		www.cuc.gov/nnsn
Comment	S:	
1		
1		
1		
1		
Dicalaire	les of trade names and commercial courses is for identification only and data and involve and are serviced.	
Discialmer: (	Use of trade names and commercial sources is for identification only and does not imply endorsement.	